Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
BioLife Solutions is the leading developer, manufacturer and supplier of proprieta...
BioLife Solutions is the leading developer, man...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company foc...
La Jolla Pharmaceutical Company is a publicly t...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the deve...
Pacira BioSciences, Inc. is a specialty pharmac...
Acasti is a biopharmaceutical innovator focused on the research, development and c...
Acasti is a biopharmaceutical innovator focused...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology compa...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a...
Join the National Investor Network and get the latest information with your interests in mind.